On Thursday, Carnival Corp (NYSE:CCL)’s shares inclined 0.56% to $49.21.
Carnival Corporation & plc (CCL), the world’s largest travel and leisure company, recently declared that the U.S. Department of the Treasury and the U.S. Department of Commerce granted approval for the company to start travel to Cuba. Carnival Corporation intends to take travelers to Cuba starting in May 2016 via its newly launched fathom brand – a new social impact travel brand providing purpose-oriented, social impact experiences, initially in the Dominican Republic.
Carnival Corporation intends to operate fathom travel itineraries directly to Cuba for the purpose of providing cultural, artistic, faith-based and humanitarian exchanges between American and Cuban citizens. Authorized under current U.S.-to-Cuba travel guidelines, the new Cuban itineraries on fathom will strictly comply with U.S. Department of Treasury rules that allow licensed travel companies to transport approved travelers to Cuba to engage in activities that support the Cuban people. Carnival Corporation is in active talk aboutions and plans to work with the appropriate authorities in Cuba so that Cuban approval is granted.
Launched June 4th as Carnival Corporation’s 10th global brand, fathom is designed as a purpose-driven brand to enrich the lives of its travelers and in the case of the Dominican Republic, drive sustainable social impact on a noteworthyscale. The brand anticipates to attract 37,000 annual travelers who collectively could spend a total of more than 100,000 days a year either volunteering or immersing in educational and cultural exchanges in local communities.
Carnival Corporation operates as a cruise company worldwide. It provides vacations to various cruise destinations. The company offers cruise services under the Carnival Cruise Lines, Holland America Line, Princess Cruises, and Seabourn brand names in North America; and AIDA Cruises, Costa Cruises, Cunard, and P&O Cruises names in Europe, Australia, and Asia. It operates 100 cruise ships. It also owns and operates 12 hotels or lodges, and about 300 motor coaches and 20 glass-domed railcars. The company sells its cruise services through retail, online and home-based agents, wholesalers, general sales agents, and tour operators. Carnival Corporation was incorporated in 1972 and is headquartered in Miami, Florida.
ACE Limited (NYSE:ACE)’s shares gained 0.83% to $103.49.
ACE Limited (ACE) declared the appointment of Peter van Ratingen as its new Country President for its general insurance operation in the Philippines. Mr. van Ratingen succeeds Mr. Daniel Daly, who will retire on July 31, 2015.
In his role as Country President, Mr. van Ratingen will oversee the operations and business development activities of ACE’s key business lines in the Philippines namely, Property & Casualty, Accident & Health and Personal & Business Insurance. He is also responsible for the administration of regulatory relationships, planned partnerships and affinity relationships. He will report to Juan Luis Ortega, Regional President for ACE’s general insurance operations in Asia Pacific.
ACE Limited, through its auxiliaries, provides a range of property and casualty insurance and reinsurance products worldwide. The company’s Insurance North American P&C segment offers casualty insurance, environmental, inland marine, professional risk, disaster protection, vacant land and building, and claims and risk administration services; homeowners, automobile, valuables, umbrella liability, and recreational marine insurance; and wholesale excess and surplus lines property, casualty, environmental, professional liability, inland marine, and product recall coverages.
At the end of Thursday’s trade, Clovis Oncology Inc (NASDAQ:CLVS)‘s shares dipped -1.05% to $78.20.
Clovis Oncology Inc (CLVS) declared updated findings from its Phase 2 clinical study of rociletinib (CO-1686), the Company’s novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations, in addition to the dominant resistance mutation T790M. These data from the TIGER-X trial are being presented recently in an oral presentation (Abstract #8001) at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates which comprise Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast and lung cancers.
Infosys Ltd ADR (NYSE:INFY), ended its Thursday’s trading session with -0.26% loss, and closed at $15.41.
Infosys (INFY), a global leader in consulting, technology, outsourcing and next-generation services, has been inducted into the ‘Winner’s Circle’ in the inaugural Engineering Services Blueprint report by leading analyst firm HfS Research. Companies that demonstrate excellence in execution and innovation are placed in the ‘Winner’s Circle’ by HfS.
Highlights:
- HfS commends Infosys for its depth of client experiences and capabilities across engineering services in all verticals.
- The report refers to over 80 Infosys case studies and customer references, which rate the company highly on agility and delivery.
- It references Infosys’ articulation of a powerful vision for technology-led innovation at the intersection of physical and digital worlds, with its engineering services right at the center of it. Expertise in composites, artificial intelligence and neural networks was highlighted.
- Knowledge-based engineering (KBE), the process of capturing knowledge created in the product development process, is stated as an Infosys strength.
Infosys Limited, together with its auxiliaries, provides business consulting, technology, engineering, and outsourcing services in North America, Europe, India, and internationally. Its solutions comprise business information technology (IT) services comprising application development and maintenance, independent validation services, infrastructure administration, business process administration, and engineering services comprising of product engineering and life cycle solutions; and consulting and systems integration services, counting consulting, enterprise solutions, systems integration, and advanced technologies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
